Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBIT: 2010-2025

Historic EBIT for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $75.5 million.

  • Ironwood Pharmaceuticals' EBIT rose 194.45% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 24.15%. This contributed to the annual value of $93.1 million for FY2024, which is 109.85% up from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' EBIT is $75.5 million, which was up 66.55% from $45.3 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' EBIT ranged from a high of $75.5 million in Q3 2025 and a low of -$1.1 billion during Q2 2023.
  • Its 3-year average for EBIT is -$69.1 million, with a median of $31.5 million in 2024.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' EBIT soared by 243.22% in 2021 and then tumbled by 2,046.17% in 2023.
  • Ironwood Pharmaceuticals' EBIT (Quarterly) stood at $56.6 million in 2021, then rose by 20.80% to $68.4 million in 2022, then plummeted by 45.02% to $37.6 million in 2023, then fell by 16.22% to $31.5 million in 2024, then surged by 194.45% to $75.5 million in 2025.
  • Its EBIT stands at $75.5 million for Q3 2025, versus $45.3 million for Q2 2025 and -$29.1 million for Q1 2025.